(BIS)SULFONAMIDE DERIVATIVES
The present invention provides bissulphonamide derivatives of formula (I), in which R represents C1-6-alkyl, C2-6-alkenyl, or NR R ,R and R each independently represent hydrogen, C1-4.alkyl, F, aryl, or C1-6.alkylaryl; R and R each represent hydrogen; R represents C1-6-alkyl; n is an integer from 7...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French |
Published |
13.12.2001
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides bissulphonamide derivatives of formula (I), in which R represents C1-6-alkyl, C2-6-alkenyl, or NR R ,R and R each independently represent hydrogen, C1-4.alkyl, F, aryl, or C1-6.alkylaryl; R and R each represent hydrogen; R represents C1-6-alkyl; n is an integer from 7 to 14; and R and R each independently represent hydrogen or C1-4-alkyl; or a pharmaceutically acceptable salt thereof. Bissulphonamide derivatives of formula (I), in which R represents C1-6-alkyl, C2-6-alkenyl, or NR R , R , R , R , and R each represent hydrogen; R represents C1-6-alkyl; n is an integer from 6 to 14; and R and R each independently represent hydrogen or C1-4-alkyl; or a pharmaceutically acceptable salt thereof; are useful for potentiating glutamate receptor function in a mammal and, therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
The present invention provides (bis)sulfonamide derivatives of formula (I) useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
La présente invention concerne des dérivés de (bis)sulfonamide représentés par la formule (I) qui conviennent pour potentialiser la fonction du récepteur de glutamate chez un mammifère et qui convient, par conséquent, pour traiter une grande variété de pathologies, telles que des troubles psychiatriques et neurologiques. |
---|---|
Bibliography: | Application Number: WO2001US10829 |